Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

The New England Journal of Medicine
Aditya BardiaKevin Kalinsky

Abstract

Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for...Continue Reading

References

Jun 4, 1998·International Journal of Cancer. Journal International Du Cancer·E RipaniS Alberti
Jun 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Huayi HuangJoseph Geradts
Jun 19, 2008·Cancer Treatment Reviews·Dinemarie KweekelHans Gelderblom
Apr 4, 2009·Cancer Causes & Control : CCC·Katrina F TriversJ William Eley
Mar 17, 2010·Breast Cancer Research and Treatment·Edith A PerezAlvaro Moreno-Aspitia
Mar 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas M CardilloDavid M Goldenberg
Mar 8, 2011·Lancet·Javier CortesUNKNOWN EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Aug 7, 2013·Hematology/oncology Clinics of North America·Carey K AndersLisa A Carey
Sep 30, 2014·The New England Journal of Medicine·Alice T ShawA John Iafrate
Mar 19, 2015·British Journal of Clinical Pharmacology·Felicia Stefania FalvellaFilippo Pietrantonio
May 7, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander N StarodubDavid M Goldenberg
Jun 25, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert M SharkeyDavid M Goldenberg
Oct 30, 2015·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Dec 9, 2016·The Breast : Official Journal of the European Society of Mastology·F CardosoE Winer
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Feb 27, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Meredith K ChukRichard Pazdur
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aditya BardiaLinda T Vahdat
Aug 18, 2017·Asia-Pacific Journal of Clinical Oncology·Parham Khosravi-ShahiSara Custodio-Cabello
Mar 6, 2018·British Journal of Clinical Pharmacology·Pau RieraDavid Páez
Jul 11, 2018·Oncotarget·David M GoldenbergRobert M Sharkey
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators

❮ Previous
Next ❯

Citations

Apr 2, 2019·Current Treatment Options in Oncology·Noam PondéMartine Piccart
Jun 13, 2019·The New England Journal of Medicine·Aditya BardiaKevin Kalinsky
Aug 10, 2019·Expert Review of Anticancer Therapy·Jennifer WeissJennifer Diamond
Jan 15, 2020·Proceedings of the National Academy of Sciences of the United States of America·En-Chi HsuTanya Stoyanova
Feb 19, 2020·Expert Opinion on Therapeutic Targets·Jane S Y SuiSteven G Gray
Mar 21, 2020·SLAS Discovery·Laurence Gauzy-LazoMarie-Priscille Brun
Apr 8, 2020·Expert Opinion on Biological Therapy·Paolo TarantinoGiuseppe Curigliano
Mar 4, 2020·The Journal of Clinical Investigation·Teresa GaglianoGeorgios Giamas
Apr 18, 2020·Expert Opinion on Biological Therapy·David M Goldenberg, Robert M Sharkey
May 27, 2020·Expert Opinion on Biological Therapy·José Pérez-GarcíaJavier Cortés
May 21, 2020·The Journal of Pathology·Katherine M RieraJames R Goldenring
Jul 2, 2020·International Journal of Molecular Sciences·Stefania CoccoMichelino De Laurentiis
Jan 3, 2020·International Journal of Molecular Medicine·Masuko Katoh, Masaru Katoh
Jul 28, 2020·Expert Opinion on Biological Therapy·Saba S Shaikh, Leisha A Emens
Aug 14, 2020·Frontiers of Medicine·Hongnan Mo, Binghe Xu
Jan 16, 2020·Antibodies·Donmienne LeungYiqing Feng
Apr 22, 2020·American Society of Clinical Oncology Educational Book·Valentina BoniAmita Patnaik
Jul 14, 2020·Current Opinion in Oncology·Eleonora NicolòGiuseppe Curigliano
Feb 23, 2020·Science Translational Medicine·Florence CoussyElisabetta Marangoni
Aug 29, 2020·Pharmaceutics·Alberto JuanCarlos Alonso-Moreno
Oct 11, 2019·Journal of breast cancer·Maryam NakhjavaniAmanda R Townsend
Apr 29, 2020·Pharmaceuticals·Puja SharmaWaldemar Debinski
Apr 23, 2020·Journal of Gynecologic Oncology·Miseon KimJae Weon Kim
Mar 28, 2020·American Society of Clinical Oncology Educational Book·Shalini Makawita, Funda Meric-Bernstam
Jun 13, 2020·Drugs·Yahiya Y Syed
Oct 12, 2019·F1000Research·Mary-Ann Bjornsti, Scott H Kaufmann
Apr 12, 2020·Cancers·Elena VagiaMassimo Cristofanilli
Mar 15, 2020·Proceedings of the National Academy of Sciences of the United States of America·Aadra P BhattMatthew R Redinbo
May 20, 2020·Therapeutic Advances in Medical Oncology·Aiko NagayamaAditya Bardia
Jun 30, 2019·Drugs·Kelly E McCannNicholas McAndrew
Jun 13, 2019·The New England Journal of Medicine·Yukinori OzakiToshimi Takano
Oct 13, 2020·Expert Opinion on Investigational Drugs·J Tanner McMahonDavid Cory Adamson
Oct 18, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Anzhelika VorobyevaVladimir Tolmachev

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

© 2022 Meta ULC. All rights reserved